Ministry of Public Health vows to treat COVID-19 There is a panel of medical experts to consider based on academic information.
Today (13 September 2022) at the Ministry of Public Health (PTI) Dr. Rungruang Kitphati, MD. Chief Adviser at Ministry Level (Dr. Qualified Level 11) and a spokesman for the Ministry of Health revealed the case of many medical scholars expressing concern about the effectiveness of favipiravir, saying that various measures related to COVID-19 in Thailand, including disease control medical treatment The MoPH operates in the form of a committee consisting of academics and specialist doctors from leading medical institutions. Take into account the information of academic education both in the country and abroad. Favipiravir was the first drug to be used since the outbreak began. which at the time was a strain that caused severe symptoms have a lung infection
“By the results of the study of the Faculty of Medicine Siriraj Hospital Mahidol University in collaboration with Bamrasnaradura Institute, Department of Disease Control and Genomics Medicine Division and support innovation Department of Medical Sciences in patients with COVID-19 with mild or moderate symptoms no pneumonia and received medication from the first day of symptom onset Follow-up assessment of symptoms in the hospital by medical personnel found that the symptoms of Covid-19 patients clearly improved faster than those who did not receive the drug. (Half improved in 2 days when administered compared to 14 days in the no drug group),” said Dr. Ruang Ruang.
A spokesman for the Ministry of Public Health said that foreign research on favipiravir was carried out at different times. There are also differences in details about Thai education and practical use. which since the use of this drug The rate of loss decreases accordingly. At present, the death rate from COVID-19 in Thailand is less than 0.1 percent, or less than 1 case in 1,000 cases, which is very low. in people younger than 18 at this time.
“The expert committee has been tracking treatment information. new research results continually related to adjust the treatment guidelines accordingly Other drugs that are supported by studies are also being used, such as remdisivir, which is an injectable drug. It has the same mechanism of action as Favipiravir. For patients with drug absorption problems can’t eat including pregnant women Molnupiravir (Molnupiravir) is an oral medication for adults. have the same mechanism of action Reduce the risk of severe symptoms It must be given within 5 days after the onset of symptoms. and Paxlovid has a mechanism of action that enzymes reduce the number of germs which is being distributed to various hospitals After receiving approval from the Center for Operations, Ministry of Public Health and the Center for Covid-19 Situation Administration (CDC), the information about the efficacy of favipiravir is currently published. Academic Committee It has been acknowledged and will be taken into consideration for further improvement of the appropriate treatment regimen,” said Dr. Rungruang.